eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

SCImago Journal & Country Rank
 
6/2006
vol. 5
 
Share:
Share:
more
 
 
abstract:

Comparison of effectiveness and tolerability of two oral low-dose formulations containing 1 mg of 17β-estradiol and either dydrogesterone or norethisterone acetate applied as continuous combined hormonal therapy in peri- and postmenopausal women

Tomasz Paszkowski

Przegląd Menopauzalny 2006; 6: 367–373
Online publish date: 2007/02/08
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Objective: To compare the effectiveness and tolerability profile of two oral low-dose formulations containing 1 mg of 17β-estradiol and either dydrogesterone or norethisterone acetate applied as continuous combined hormonal therapy (ccHT) in peri- and postmenopausal women.
Material and methods: The studied population consisted of 60 peri- or postmenopausal women aged 45-55 qualified for the continuous combined hormonal therapy. The patients were divided in two equally numerous groups receiving either Femoston Conti® or Activelle®. The following parameters were evaluated during the 3 months observation period: menopausal symptoms (Greene Scale), depressive mood (Beck’s Inventory), sexual life quality (Female Sexual Function Index) and the presence of unwanted effects. Results and conclusions: 1. Low-dose oral hormonal therapy with the use of 1 mg estradiol and either dydrogesterone or norethisterone acetate (NETA) effectively and rapidly eliminates climacteric symptoms of both vasomotoric and psychogenic character. 2. The use of biologically strong progestagen, such as NETA, in ccHT results in better bleeding profile as compared to the use of dydrogesterone. 3. After 3 monts of treatment with low dose formulation for ccHT containing 1 mg of estradiol and 0.5 mg of NETA, libido improves significantly.
keywords:

low-dose hormonal replacement therapy, dydrogesterone, norethisterone acetate, quality of life, tolerability

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe